The Upstream Partner for Combinatorial Success
Every major immuno-oncology modality depends on one biological input: an immune system that can already recognize the tumor. In many solid-tumor patients, that input is missing.
XIRT™ is designed to rebuild it.
Running on the OmniAntigen™ Platform, XIRT™ preserves the patient's complete tumor antigen repertoire and presents it with synchronized cGAS-STING activation, designed to generate the tumor-specific T cells that checkpoint and cellular franchises presuppose but cannot create on their own.
XIRT™ is the upstream immune-priming layer that immuno-oncology can build on.
Why Upstream, Why Now
The first era of immuno-oncology released the brakes. The next era is about supply. Checkpoint inhibitors, bispecifics, and cell therapies all assume that tumor-specific T cells already exist and simply need to be unleashed. In immunologically cold, checkpoint-refractory tumors, that assumption breaks, and the most advanced downstream asset has nothing to act on.
XIRT changes the input, not the rules. By rebuilding the missing T cell repertoire upstream, XIRT is designed to turn the cold-tumor majority from a population that defeats combination strategies into one that combination strategies can reach. For a partner, this is the opportunity to extend an existing franchise into the largest unsolved gap in solid-tumor oncology.
Two Ways to Partner
Novastra offers two distinct partnership tracks for combination-oncology developers, each built to amplify an existing franchise rather than displace it.
Upstream of Checkpoint and Cellular Franchises
OAP-101 is engineered to sit directly upstream of anti-PD-1 checkpoint blockade and cell-based franchises, restoring antigen visibility before the downstream agent acts. It is an upstream immune primer, built to be given in combination with the checkpoint therapies it is designed to potentiate, never as a standalone agent. By rebuilding the tumor-specific T cell repertoire first, OAP-101 is designed to extend the reach of PD-1 inhibitors into checkpoint-refractory solid tumors where monotherapy benefit remains low, a market-expanding effect rather than a market-splitting one.
When checkpoint inhibitors release the brakes, the immune system already knows exactly what to fight.
Antibody-Drug Conjugate, Radiotherapy, and Chemotherapy Companions
In Situ Companion for ADC, Radiotherapy,
and Chemotherapy Franchises
OAP-103 extends the OmniAntigen™ Platform into an off-the-shelf, in situ format, delivered as a programmable reagent kit rather than a patient-specific manufactured product. It is engineered as an immune companion for the franchises that define the cytotoxic combination era. When an antibody-drug conjugate (ADC), radiotherapy, or chemotherapy regimen disrupts tumor cells in situ, OAP-103 is designed to capture and re-present the dynamic neoantigens those downstream therapies release, with the aim of converting a wave of cytotoxic destruction into a programmed, cold-to-hot immune event.
Its lead setting is immunologically cold, checkpoint-refractory solid tumors, central to the antibody-drug-conjugate era and exactly where downstream cytotoxic franchises generate antigen but no durable immunity. OAP-103 is preclinical, designed for drug-product accessibility rather than cell-therapy logistics, and represents a partnership track structurally distinct from OAP-101, additive across the major combination-oncology franchises of leading global partners.
Antibody-Drug Conjugate, Radiotherapy, and Chemotherapy Companions
Why Partner with Novastra
A New Upstream Modality
XIRT™ introduces systematic immune priming upstream of existing therapies, while the OmniAntigen™ Platform preserves protein and non-protein antigens without computational down-selection.
Human Clinical Evaluation
OAP-101 is in an active investigator-initiated Phase 1 proof-of-concept study, with interim investigator-assessed observations of immune activation in a demanding checkpoint-refractory population.
DISCLAIMER：OAP-101 is investigational. Interim observations from an early-stage study do not establish safety or efficacy.
Combination-Native Design
OAP-101 is built to precede checkpoint and cellular therapies. OAP-103 is built to accompany the cytotoxic franchises partners already own.
Platform Leverage
The OmniAntigen™ Platform spans multiple formats, indications, and partnership paths rather than a single point asset. One Platform. Every Indication.
Antibody-Drug Conjugate, Radiotherapy, and Chemotherapy Companions
Platform-Addressable Markets
The OmniAntigen™ Platform is built for immunologically cold, checkpoint-refractory solid tumors. Expansion opportunities under exploration include:
-
Ovarian cancer
-
Triple-negative breast cancer
-
Adjuvant applications in surgical oncology
-
Combinations with antibody-drug conjugates
The OmniAntigen™ Platform is built for partnership across combination oncology.
Let’s Transform
Cancer Care Together
Novastra welcomes partnership discussions with pharmaceutical companies and academic institutions, by warm introduction. A confidential data package is available under NDA. To explore collaboration opportunities, contact us at partnerships@novastra.bio.